Insider · CIK 0001875588
Saloni S. Varma
Files at THRN (Thorne Healthtech, Inc.). First filing -, latest -.
In brief
Saloni S. Varma files SEC Form 4 as CFO and director at THRN (Thorne Healthtech, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Saloni S. Varma has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 16, 2023 | THRN Thorne Healthtech, Inc. | DDisposition to issuer Common Stock | -581,643 | - | - | 0 | Oct 18, 2023 |
| Apr 4, 2023 | THRN Thorne Healthtech, Inc. | FTax withholding Common Stock | -3,454 | $4.72 | $16k | 81,643 | Oct 18, 2023 |
| Apr 4, 2023 | THRN Thorne Healthtech, Inc. | FTax withholding Common Stock | -6,430 | $4.72 | $30k | 78,667 | Apr 6, 2023 |
| Apr 4, 2023 | THRN Thorne Healthtech, Inc. | AGrant or award Common Stock | +500,000 | $0.00 | $0 | 578,667 | Apr 6, 2023 |
Questions about Saloni S. Varma
Answered from the filings on this page, as of the latest one.
Is Saloni S. Varma buying or selling?
Saloni S. Varma has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Saloni S. Varma's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Saloni S. Varma has 0.
Where does Saloni S. Varma file Form 4?
Saloni S. Varma has filed Form 4 at THRN (Thorne Healthtech, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.